Deep-Dive: JX10 — A Late-Window Anti-Inflammatory Thrombolytic Hits Phase 2a Safety Mark August 18, 2026
Deep-Dive: ETLAS-2 — Tadalafil for CSVD Fails Feasibility, but the Imaging Signal Hints at a Better Trial August 14, 2026